Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Imipramine Pamoate

FDA-approved product (capsule, oral), marketed as Imipramine Hydrochloride, Janimine, Pramine and 4 more.

Registered studies
49
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Imipramine Pamoate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Depressive disorder
  • Enuresis
  • Major depressive disorder

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Non-selective monoamine reuptake inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA15.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli24.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae13.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis54.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

49registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Imipramine Pamoate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-4.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-5.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-5.6 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Imipramine Pamoate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Efficacy of Online CBT for GAD Compared to Pharmaceutical Interventions

    NCT04478526 · start 2020-04-29

    Registered record
    Registry ID
    NCT04478526
    Conditions
    Generalized Anxiety Disorder
    Interventions
    SSRIs/SNRIs (Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors); Electronic Cognitive Behavioural Therapy
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2020-04-29
    Completion
    2021-05-01
    Enrolment
    115

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGeneralized Anxiety Disorder
    InterventionSSRIs/SNRIs (Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors); Electronic Cognitive Behavioural Therapy
    PhaseNot applicable
    Registry statusCompleted

  • Gustatory Dysfunction Among a Sample of Depressed Egyptian Adults Under Anti-depressants Therapy

    NCT03599011 · start 2020-02-22

    Registered record
    Registry ID
    NCT03599011
    Conditions
    Taste Disorders
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-02-22
    Completion
    2020-10-07
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTaste Disorders
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Gustatory Modulators Among a Sample of Depressed Egyptian Adults Under Anti-depressants Therapy

    NCT04923425 · start 2020-02-22

    Registered record
    Registry ID
    NCT04923425
    Conditions
    Taste Disorders
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-02-22
    Completion
    2020-10-07
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTaste Disorders
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Imipramine on ER+ve and Triple Negative Breast Cancer

    NCT03122444 · start 2019-07-05

    Registered record
    Registry ID
    NCT03122444
    Conditions
    Breast Cancer
    Interventions
    Imipramine
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2019-07-05
    Completion
    2022-05-01
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionImipramine
    PhaseEarly phase 1
    Registry statusCompleted

  • Does Single Dose Imipramine Affect the Opening Pressure of the Urethral and Anal Sphincter?

    NCT03102645 · start 2017-05-16

    Registered record
    Registry ID
    NCT03102645
    Conditions
    Urinary Incontinence, Stress; Fecal Incontinence
    Interventions
    Placebo Oral Tablet; Imipramine Hydrochloride 25 MG
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-05-16
    Completion
    2017-06-21
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Incontinence, Stress; Fecal Incontinence
    InterventionPlacebo Oral Tablet; Imipramine Hydrochloride 25 MG
    PhasePhase 1
    Registry statusCompleted

  • The Efficacy of Peer Support Model for Depression Care in Patients With Diabetes Mellitus

    NCT03055468 · start 2017-04-01

    Registered record
    Registry ID
    NCT03055468
    Conditions
    Diabetes Mellitus; Depression
    Interventions
    Peer support
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2017-04-01
    Completion
    2018-03-30
    Enrolment
    130

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus; Depression
    InterventionPeer support
    PhaseNot applicable
    Registry statusUnknown

  • Effectiveness of Qufeng Shengshi Fang on Treatment of Allergic Rhinitis.

    NCT02653339 · start 2016-06

    Registered record
    Registry ID
    NCT02653339
    Conditions
    Rhinitis, Allergic, Perennial
    Interventions
    Qufeng Shengshi Fang and Loratadine; Loratadine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2016-06
    Completion
    2018-08
    Enrolment
    180

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRhinitis, Allergic, Perennial
    InterventionQufeng Shengshi Fang and Loratadine; Loratadine
    PhaseNot applicable
    Registry statusUnknown

  • Mindfulness Training for Children With Attention-Deficit/Hyperactivity Disorder (ADHD) and Mindful Parenting

    NCT03220308 · start 2016-02-18

    Registered record
    Registry ID
    NCT03220308
    Conditions
    Attention Deficit Hyperactivity Disorder
    Interventions
    MYmind mindfulness training; Care-as-usual for children (8-16 years old) with ADHD
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2016-02-18
    Completion
    2019-02-22
    Enrolment
    103

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAttention Deficit Hyperactivity Disorder
    InterventionMYmind mindfulness training; Care-as-usual for children (8-16 years old) with ADHD
    PhaseNot applicable
    Registry statusCompleted

  • Pharmacovigilance in Gerontopsychiatric Patients

    NCT02374567 · start 2015-01

    Registered record
    Registry ID
    NCT02374567
    Conditions
    Dementia; Depression; Schizophrenia; Psychosomatic Disorders; Anxiety Disorders
    Interventions
    Phenobarbital; Phenytoin; Carbamazepine; Oxcarbazepine; Valproic Acid; Lamotrigine; Topiramate; Gabapentin; Levetiracetam; Pregabalin; Lacosamide; Clonazepam; Biperiden; Levomepromazine; Fluphenazine; Perphenazine; Perazine; Thioridazine; Haloperidol; Melperone; Pipamperone; Bromperidol; Benperidol; Sertindole; Ziprasidone; Flupentixol; Chlorprothixene; Zuclopenthixol; Fluspirilene; Pimozide; Clozapine; Olanzapine; Quetiapine; Sulpiride; Tiapride; Amisulpride; Prothipendyl; Risperidone; Aripiprazole; Paliperidone; Diazepam; Oxazepam; Lorazepam; Bromazepam; Clobazam; Alprazolam; Hydroxyzine; Buspirone; Chloral Hydrate; Flurazepam; Nitrazepam; Triazolam; Lormetazepam; Temazepam; Midazolam; Brotizolam; Zopiclone; Zolpidem; Zaleplon; Melatonin; Clomethiazole; Diphenhydramine; Promethazine; Imipramine; Clomipramine; Opipramol; Trimipramine; Amitriptyline; Nortriptyline; Doxepin; Maprotiline; Amitriptyline oxide; Fluoxetine; Citalopram; Paroxetine; Sertraline; Fluvoxamine; Escitalopram; Tran
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2015-01
    Completion
    2017-06-28
    Enrolment
    407

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDementia; Depression; Schizophrenia; Psychosomatic Disorders +1 more
    InterventionPhenobarbital; Phenytoin; Carbamazepine; Oxcarbazepine +75 more
    PhasePhase 3
    Registry statusTerminated

  • YouScript IMPACT Registry

    NCT02191358 · start 2014-10

    Registered record
    Registry ID
    NCT02191358
    Conditions
    Adverse Drug Events; Adverse Drug Reactions; Drug Interaction Potentiation; Drug Metabolism, Poor, CYP2D6-RELATED; Drug Metabolism, Poor, CYP2C19-RELATED; Cytochrome P450 Enzyme Deficiency; Cytochrome P450 CYP2D6 Enzyme Deficiency; Cytochrome P450 CYP2C9 Enzyme Deficiency; Cytochrome P450 CYP2C19 Enzyme Deficiency; Cytochrome P450 CYP3A Enzyme Deficiency; Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant; Poor Metabolizer Due to Cytochrome P450 CYP2C19 Variant; Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2014-10
    Completion
    2015-08
    Enrolment
    800

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdverse Drug Events; Adverse Drug Reactions; Drug Interaction Potentiation; Drug Metabolism, Poor, CYP2D6-RELATED +9 more
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Supplemental Transcranial Magnetic Stimulation (TMS) vs. Standard Medication Monotherapy for Treating Major Depression: An Exploratory Field Study

    NCT01944657 · start 2013-09

    Registered record
    Registry ID
    NCT01944657
    Conditions
    1. Major Depressive Disorder
    Interventions
    Supplemental TMS; Standard Medication Monotherapy
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    2013-09
    Completion
    2015-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    Condition1. Major Depressive Disorder
    InterventionSupplemental TMS; Standard Medication Monotherapy
    PhaseNot applicable
    Registry statusWithdrawn

  • Interpersonal Psychotherapy for Treatment Resistant Depression

    NCT01896349 · start 2013-04

    Registered record
    Registry ID
    NCT01896349
    Conditions
    Treatment Resistant Depression
    Interventions
    IPT+ antidepressant drugs; fluoxetine; sertraline; paroxetine; Citalopram; escitalopram; fluvoxamine; Venlafaxine; Duloxetine; Bupropion; Lithium; Risperidone; tranylcypromine; Imipramine; amitriptyline; Clomipramine; nortriptyline; trazodone; Mirtazapine; sulpiride
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2013-04
    Completion
    2014-11
    Enrolment
    74

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTreatment Resistant Depression
    InterventionIPT+ antidepressant drugs; fluoxetine; sertraline; paroxetine +16 more
    PhaseNot applicable
    Registry statusUnknown

  • Efficacy of Imipramine for Treatment of Patients With Esophageal Hypersensitivity/ Functional Heartburn

    NCT01753128 · start 2012-12

    Registered record
    Registry ID
    NCT01753128
    Conditions
    Gastroesophageal Reflux Disease
    Interventions
    imipramine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-12
    Completion
    2013-09
    Enrolment
    83

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastroesophageal Reflux Disease
    Interventionimipramine
    PhasePhase 3
    Registry statusCompleted

  • Imipramine Treatment for Patients With Multi-organ Bodily Distress Syndrome

    NCT01518634 · start 2012-01

    Registered record
    Registry ID
    NCT01518634
    Conditions
    Somatisation Disorder; Somatoform Disorders
    Interventions
    Imipramine treatment; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-01
    Completion
    2016-12
    Enrolment
    138

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSomatisation Disorder; Somatoform Disorders
    InterventionImipramine treatment; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Linking Altered Central Pain Processing and Genetic Polymorphism to Drug Efficacy in Chronic Low Back Pain (Predictio)

    NCT01179828 · start 2010-07

    Registered record
    Registry ID
    NCT01179828
    Conditions
    Low Back Pain
    Interventions
    Oxycodone 15mg; Clobazam; Imipramine; Tolterodine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-07
    Completion
    2015-12
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLow Back Pain
    InterventionOxycodone 15mg; Clobazam; Imipramine; Tolterodine
    PhasePhase 3
    Registry statusCompleted